Search by Drug Name or NDC
NDC 00006-3069-01 PIFELTRO 100 mg/1 Details
PIFELTRO 100 mg/1
PIFELTRO is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is DORAVIRINE.
MedlinePlus Drug Summary
Doravirine is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults who have not been treated with other HIV medications. It is also used to replace current medication therapy in certain people already taking HIV medications. Doravirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although doravirine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 00006-3069-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Doravirine
Product Information
| NDC | 00006-3069 |
|---|---|
| Product ID | 0006-3069_15d3431d-2abc-4a2a-ab4e-de1c5ed3a95b |
| Associated GPIs | 12109025000320 |
| GCN Sequence Number | 078887 |
| GCN Sequence Number Description | doravirine TABLET 100 MG ORAL |
| HIC3 | W5K |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NON-NUCLEOSIDE, RTI |
| GCN | 45294 |
| HICL Sequence Number | 045216 |
| HICL Sequence Number Description | DORAVIRINE |
| Brand/Generic | Brand |
| Proprietary Name | PIFELTRO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | doravirine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | DORAVIRINE |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA210806 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00006-3069-01 (00006306901)
| NDC Package Code | 0006-3069-01 |
|---|---|
| Billing NDC | 00006306901 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (0006-3069-01) |
| Marketing Start Date | 2018-07-20 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 57.0465 |
| Pricing Unit | EA |
| Effective Date | 2024-01-06 |
| NDC Description | PIFELTRO 100 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |